DSIP
DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide, meaning it consists of nine amino acids, that has been investigated for its relationship with sleep physiology, circadian processes, and neuroendocrine regulation. Early research identified DSIP in connection with slow-wave, or delta, sleep, which led to its name and decades of experimental investigation.
Research involving DSIP has explored its potential influence on sleep initiation, sleep architecture, circadian rhythms, and physiological processes associated with the sleep-wake cycle. Researchers have also investigated DSIP-like activity in relation to neurotransmitter signaling, hormonal regulation, stress responses, and other neurophysiological processes.
Small human studies have examined synthetic DSIP in both healthy volunteers and individuals experiencing insomnia. Some early experiments reported changes in measures such as sleep latency, total sleep time, or sleep efficiency. However, results have not been consistently strong across studies. A later double-blind study in chronic insomnia concluded that the observed effects were weak and that short-term DSIP treatment was unlikely to provide major therapeutic benefit.
For that reason, DSIP is best presented as an experimental research peptide associated with the scientific study of sleep and circadian physiology, rather than as a proven sleep aid or treatment for insomnia.
For laboratory research purposes only. Not for human consumption.
Graf & Kastin, 1984, Neuroscience & Biobehavioral Reviews: A broad review of DSIP covering its characterization as a nonapeptide and research involving sleep, circadian patterns, neurotransmitters and hormonal activity.
Schneider-Helmert et al., 1981: An early controlled human study in six healthy volunteers examining synthetic DSIP and subsequent sleep behavior, including total sleep time, sleep onset and sleep efficiency.
Bes et al., 1992, Neuropsychobiology: Particularly useful for keeping our claims balanced. This double-blind study involved 16 people with chronic insomnia. Some measures improved, but the authors concluded the effects were weak and DSIP was unlikely to provide major therapeutic benefit for chronic insomnia.
Seifritz et al., 1995, Peptides: Examined naturally occurring DSIP-like immunoreactivity in healthy subjects across sleep, sleep deprivation and recovery sleep, finding changes associated with the transition from wakefulness to sleep.
Those four support the description nicely while making it clear that DSIP is an experimental research peptide, not an established insomnia treatment.
